Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Holdhoff M, Ye X, Strowd RE, Nabors B, Walbert T, Lieberman FS, Bagley SJ, Fiveash JB, Fisher JD, Desideri S, Surakus T, Engelhardt M, Kaindl T, Lane HA, Litherland K, Grossman SA, Kleinberg LR. Holdhoff M, et al. Among authors: lieberman fs. Neurooncol Adv. 2024 Aug 28;6(1):vdae150. doi: 10.1093/noajnl/vdae150. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39371261 Free PMC article.
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN, Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA, Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K, Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S, Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY, Ligon KL, Beroukhim R. Rendo V, et al. Among authors: lieberman f. medRxiv [Preprint]. 2024 Aug 14:2024.08.12.24311893. doi: 10.1101/2024.08.12.24311893. medRxiv. 2024. PMID: 39211865 Free PMC article. Preprint.
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR).
Ahluwalia MS, Ozair A, Rudek M, Ye X, Holdhoff M, Lieberman FS, Piotrowski AF, Nabors B, Desai A, Lesser G, Huang RC, Glenn S, Khosla AA, Peereboom DM, Wen PY, Grossman SA. Ahluwalia MS, et al. Among authors: lieberman fs. Cell Rep Med. 2024 Jul 16;5(7):101630. doi: 10.1016/j.xcrm.2024.101630. Epub 2024 Jul 1. Cell Rep Med. 2024. PMID: 38955178 Free PMC article. Clinical Trial.
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma.
Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. Casillo SM, et al. Among authors: lieberman fs. Cell Rep. 2024 Jan 23;43(1):113557. doi: 10.1016/j.celrep.2023.113557. Epub 2023 Dec 18. Cell Rep. 2024. PMID: 38113141 Free article.
A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM).
Kleinberg L, Ye X, Supko J, Stevens GHJ, Shu HK, Mikkelsen T, Lieberman F, Lesser G, Lee E, Grossman S. Kleinberg L, et al. Among authors: lieberman f. Res Sq [Preprint]. 2023 Oct 24:rs.3.rs-3466927. doi: 10.21203/rs.3.rs-3466927/v1. Res Sq. 2023. Update in: J Neurooncol. 2023 Dec;165(3):499-507. doi: 10.1007/s11060-023-04514-0 PMID: 37961385 Free PMC article. Updated. Preprint.
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Strowd R, Ellingson B, Raymond C, Yao J, Wen PY, Ahluwalia M, Piotrowski A, Desai A, Clarke JL, Lieberman FS, Desideri S, Nabors LB, Ye X, Grossman S. Strowd R, et al. Among authors: lieberman fs. J Neurooncol. 2023 Oct;165(1):101-112. doi: 10.1007/s11060-023-04456-7. Epub 2023 Oct 21. J Neurooncol. 2023. PMID: 37864646 Free PMC article. Clinical Trial.
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Nisnboym M, Vincze SR, Xiong Z, Sneiderman CT, Raphael RA, Li B, Jaswal AP, Sever RE, Day KE, LaToche JD, Foley LM, Karimi H, Hitchens TK, Agnihotri S, Hu B, Rajasundaram D, Anderson CJ, Blumenthal DT, Pearce TM, Uttam S, Nedrow JR, Panigrahy A, Pollack IF, Lieberman FS, Drappatz J, Raphael I, Edwards WB, Kohanbash G. Nisnboym M, et al. Among authors: lieberman fs. Cancer Res Commun. 2023 Jul 6;3(7):1173-1188. doi: 10.1158/2767-9764.CRC-22-0434. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37426447 Free PMC article.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Fanucci K, et al. Among authors: lieberman fs. Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36968138 Free PMC article. Clinical Trial.
143 results